Perceptive Life Sciences, a fund that has outperformed the market, sold all of its 1 million shares of Novavax in the first few months of 2021 and bought millions more shares of three biopharma/biotech stocks in the same period.
The small-cap biopharmaceutical stock featured in today’s article is a Buy according to the consensus among analysts, who see upside potential of nearly 200% from current levels.
The company featured in today’s article finds itself at the intersection of biotech and cannabis – an intersection that could be worth $50 billion by 2029.
The two biotechs that are the focus of today’s article have been hot this year, with shares of both having experienced triple-digit growth. The reason? Their respective COVID-19 vaccine development programs, which have moved at lightning-fast speed.